Trial Profile
A study evaluating effect of Dapagliflozin on renal vasodilating capacity in hypertensive patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Hydrochlorothiazide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 04 Jun 2019 Results published in the Journal of Clinical Endocrinology and Metabolism
- 22 Oct 2018 New trial record
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes